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T
he occurrence of primary measles vaccine 
failure, where individuals fail to respond to 
their first dose of vaccine, is known to occur 
in around 5% of those vaccinated. This observation 
has led to the global policy for measles control rec-
ommending two doses of measles vaccination. Sec-
ondary vaccine failure, where individuals respond 
to vaccination but lose protective antibody over 
time, is less well quantified. Studying secondary 
failure is difficult, because it requires documenta-
tion of the initial response to vaccination and be-
cause confirmation of the diagnosis using standard 
serological assays is not straightforward. Despite 
this, secondary infection, as defined by a boost in 
IgG with high avidity IgG, in a patient with a his-
tory of previous infection or vaccination, has been 
associated with classical, mild atypical and even 
asymptomatic measles infection.1–4 
The routine availability of RT-PCR (reverse 
transcription–polymerase chain reaction) to detect 
low levels of measles RNA, however, has made 
the confirmation of secondary infections more 
straightforward. The study by Mitchell and 
colleagues in this issue5 systematically compares 
disease severity in vaccinated and unvaccinated 
cases. This study confirms previous observations 
that the course of measles infection is less severe 
in vaccinated than unvaccinated cases. The high 
proportion of cases with documentation of two 
doses of vaccine and the absence of IgM positivity 
suggests that most of these cases were secondary 
failures. Although the authors make no attempt 
to estimate the frequency of secondary failure, it 
suggests that most countries with high cover-
age of vaccination should expect to observe such 
cases during measles outbreaks. Given the less 
severe presentation and the absence or low level 
of IgM in many cases, however, detection of such 
infections through routine surveillance requires 
the use of a less specific case definition and the 
availability of specialist microbiology, including 
measles RT-PCR and IgG antibody avidity. 
The real public health question, however, is 
whether secondary infection from waning im-
munity could support measles transmission in 
highly vaccinated communities. As it is likely 
that unrecognised mild or unapparent secondary 
infections occur more frequently than observed 
in routine surveillance, secondary infection 
has potential to seriously impede global control 
strategies. No convincing evidence of secondary 
failures contributing to transmission has been 
published, and it has been hypothesised that high 
attack rates in vaccinees only occur under condi-
tions of intense exposure.6 This would suggest 
that secondary infections may be less transmissi-
ble, as recently confirmed in a household study of 
mumps cases in the Netherlands.7 These conclu-
sions would be consistent with the observation 
of sustained measles elimination in populations 
with high vaccination coverage, including those 
where many individuals were vaccinated more 
than 40 years earlier.
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